- IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price
- Carnival CEO Aims to Bust the Biggest Myths About the Cruise Industry
- Boomers' Biggest Retirement Regret? They Didn't Work Longer
- Shadow Work: How Businesses Are Turning Us All Into Unpaid Laborers
- America's 10 Favorite Fast-Food Burgers
The stock remains high despite concerns about an old research scandal.
The dispute centers on an error in an SEC filing by the patent monetization company.
Offerings in the U.S. that could raise up to $40 billion are in the pipeline, with Alibaba accounting for half the total, according to new data.
Short seller Andrew Left alleges the company and some underwriters withheld material information.